Illumina, Inc. (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday.

Several other brokerages have also recently issued reports on ILMN. Deutsche Bank AG reissued a “hold” rating and set a $175.00 target price (up previously from $165.00) on shares of Illumina in a report on Saturday, April 29th. Cantor Fitzgerald raised their target price on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a report on Wednesday, April 26th. Cowen and Company reissued an “outperform” rating and set a $200.00 target price on shares of Illumina in a report on Wednesday, April 26th. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $195.67 target price for the company. in a report on Tuesday, April 25th. Finally, Morgan Stanley reissued an “underweight” rating and set a $115.00 target price (up previously from $108.00) on shares of Illumina in a report on Monday, May 15th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $166.54.

Shares of Illumina (NASDAQ:ILMN) traded down 0.474% during midday trading on Tuesday, hitting $173.165. 496,645 shares of the stock were exchanged. The firm’s 50-day moving average is $175.17 and its 200-day moving average is $171.09. The stock has a market cap of $25.28 billion, a price-to-earnings ratio of 35.047 and a beta of 0.84. Illumina has a 12 month low of $119.37 and a 12 month high of $189.48.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million during the quarter, compared to analysts’ expectations of $590.51 million. During the same quarter last year, the company posted $0.71 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. Equities research analysts predict that Illumina will post $3.63 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/07/25/bidaskclub-lowers-illumina-inc-ilmn-to-strong-sell.html.

In other news, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $184.75, for a total value of $26,788.75. Following the transaction, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the transaction, the director now directly owns 534,176 shares in the company, valued at $91,221,235.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 125,248 shares of company stock worth $22,281,673. Insiders own 1.60% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. First Citizens Bank & Trust Co. increased its position in Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after buying an additional 12 shares in the last quarter. Patten Group Inc. increased its position in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares in the last quarter. Forte Capital LLC ADV increased its position in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock valued at $373,000 after buying an additional 35 shares in the last quarter. Gemmer Asset Management LLC increased its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its position in Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after buying an additional 38 shares in the last quarter. 93.75% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.